University of Iowa Hospitals & Clinics
University of Iowa Hospitals & Clinics
Iowa City, Iowa, United States31 results ยท Page 1 of 2
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| An Open-Label Study of CTI-1601 in Subjects With Friedreich's Ataxia | Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Friedreich ataxia, Nutritional and Metabolic Diseases, Spinocerebellar Degenerations, brain disorder, central nervous system disorder, cerebellar disorder, hereditary disease, inborn mitochondrial metabolism disorder, inherited neurodegenerative disorder, metabolic disease, nervous system disorder, neurodegenerative disease, spinal cord disorder | Recruiting | Phase 2 | 2026-10-09 | NCT06447025 | |
| Study to Evaluate the Safety and Efficacy of Larsucosterol in Participants With Alcohol-associated Hepatitis (AH) | Chemically-Induced Disorders, Digestive System Diseases, alcohol-induced disorders, alcohol-related disorders, alcoholic hepatitis, alcoholic liver disease, hepatitis, liver disorder, substance-related disorder | Recruiting | Phase 3 | 2026-10-06 | NCT07428538 | |
| Strategy for Improving Stroke Treatment Response | brain disorder, cardiovascular disorder, central nervous system disorder, cerebrovascular disorder, ischemic stroke, nervous system disorder, stroke disorder, vascular disorder | Recruiting | Phase 2 | 2026-10-02 | NCT05948566 | |
| Study of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSCLC (RASolve 301) | Neoplasms by Site, Thoracic Neoplasms, bronchial neoplasm, bronchogenic carcinoma, lung disorder, lung neoplasm, neoplasm, non-small cell lung carcinoma, respiratory system disorder, respiratory tract neoplasm | Recruiting | Phase 3 | 2026-09-29 | NCT06881784 | |
| Disease Modifying Potential of 5mg of Melatonin on Cognition and Brain Health in Aging | Cognition Disorders, Cognitive Decline, Cognitive Dysfunction, Mild Cognitive Impairment, cognitive disorder, psychiatric disorder | Recruiting | Not applicable | 2026-09-28 | NCT03954899 | |
| Survivorship of Attune Primary Total Knee Prosthesis | arthritic joint disease, arthropathy, musculoskeletal system disorder, osteoarthritis, rheumatic disorder | Active, not recruiting | Not applicable | 2026-09-28 | NCT01754363 | |
| A Study of the Safety and Effectiveness of the Mentor Larger Size MemoryGel Ultra High Profile Breast Implants in Subjects Who Are Undergoing Primary Breast Reconstruction or Revision Reconstruction | Breast Reconstruction; Revision Breast Reconstruction | Active, not recruiting | Not applicable | 2026-09-25 | NCT02724371 | |
| Edwards PASCAL Transcatheter Valve Repair System Pivotal Clinical Trial | cardiovascular disorder, heart disorder, heart valve disorder, tricuspid valve disorder, tricuspid valve insufficiency | Recruiting | Not applicable | 2026-09-14 | NCT04097145 | |
| Conditioning SCID Infants Diagnosed Early | severe combined immunodeficiency | Active, not recruiting | Phase 2 | 2026-08-28 | NCT03619551 | |
| A Study to Evaluate Efficacy and Safety of an Investigational Drug Named Volixibat in Patients With Itching Caused by Primary Biliary Cholangitis | Digestive System Diseases, Fibrosis, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Pruritus, Signs and Symptoms, Skin Manifestations, Skin and Connective Tissue Diseases, bile duct disorder, biliary tract disorder, cholangitis, cholestasis, cirrhosis of liver, intrahepatic cholestasis, liver disorder, primary biliary cholangitis, skin disorder | Active, not recruiting | Phase 2 | 2026-08-25 | NCT05050136 | |
| Safety and Tolerability of Ziftomenib Combinations in Patients With Relapsed/Refractory Acute Myeloid Leukemia | Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, Neoplasms by Site, acute leukemia, acute myeloid leukemia, acute myeloid leukemia with mutated NPM1, hematologic disorder, hematopoietic and lymphoid system neoplasm, leukemia, myeloid leukemia, neoplasm | Recruiting | Phase 1 | 2026-08-20 | NCT06001788 | |
| Validation of Early Prognostic Data for Recovery Outcome After Stroke for Future, Higher Yield Trials | Stroke, Acute, brain disorder, cardiovascular disorder, central nervous system disorder, cerebrovascular disorder, ischemic stroke, nervous system disorder, stroke disorder, vascular disorder | Recruiting | Not stated | 2026-08-20 | NCT05338697 | |
| Edwards PASCAL CLASP IID/IIF Pivotal Clinical Trial | cardiovascular disorder, heart disorder, heart valve disorder, mitral valve insufficiency | Active, not recruiting | Not applicable | 2026-07-08 | NCT03706833 | |
| Antibiotic Prophylaxis in High-Risk Arthroplasty Patients | Body Weight, Chronic Disease, Chronic Kidney Diseases, Disease Attributes, Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Male Urogenital Diseases, Nutritional and Metabolic Diseases, Overweight, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Signs and Symptoms, Urogenital Diseases, autoimmune disease, chronic renal failure syndrome, diabetes mellitus, endocrine system disorder, glucose metabolism disease, immune system disorder, inflammatory disease, kidney disorder, kidney failure, metabolic disease, methicillin-resistant staphylococcus aureus infectious disease, nutritional disorder, obesity disorder, overnutrition, urinary system disorder | Enrolling by invitation | Phase 4 | 2026-07-06 | NCT04297592 | |
| The Biomarkers in the Hyperbaric Oxygen Brain Injury Treatment Trial (BioHOBIT) | Brain Injuries, Traumatic, Charcot-Marie-Tooth disease type 1F, Craniocerebral Trauma, brain disorder, brain injury, central nervous system disorder, injury, nervous system disorder, nervous system injury | Recruiting | Not stated | 2026-06-22 | NCT04855396 | |
| Single Arm Study of Neoadjuvant Dostarlimab in Stage II and III Deficient Mismatch Repair Colon Cancers | Digestive System Diseases, Digestive System Neoplasms, Neoplasms by Site, colonic disorder, colonic neoplasm, colorectal neoplasm, digestive system disorder, digestive system neoplasm, intestinal disorder, malignant colon neoplasm, neoplasm | Recruiting | Phase 2 | 2026-06-12 | NCT05239546 | |
| Trial to Evaluate Safety And Effectiveness of Mechanical Circulatory Support in Patients With Advancing Heart Failure | cardiovascular disorder, heart disorder, heart failure, hypertensive disorder, lung disorder, pulmonary hypertension, respiratory system disorder, vascular disorder | Recruiting | Not applicable | 2026-06-10 | NCT06526195 | |
| KO-2806 Monotherapy and Combination Therapies in Advanced Solid Tumors | Digestive System Diseases, Digestive System Neoplasms, Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Male Urogenital Diseases, Neoplasms by Histologic Type, Neoplasms by Site, Thoracic Neoplasms, Urogenital Diseases, Urogenital Neoplasms, adenocarcinoma, benign urinary system neoplasm, bronchial neoplasm, bronchogenic carcinoma, carcinoma, colonic disorder, colorectal neoplasm, digestive system disorder, digestive system neoplasm, epithelial neoplasm, intestinal disorder, kidney cancer, kidney disorder, lung disorder, lung neoplasm, neoplasm, non-small cell lung carcinoma, rectal disorder, renal cell carcinoma, respiratory system disorder, respiratory tract neoplasm, urinary system disorder | Recruiting | Phase 1 | 2026-06-08 | NCT06026410 | |
| CREST-2 Long-term Observational Extension Study | Arterial Occlusive Diseases, brain disorder, cardiovascular disorder, carotid artery disorder, carotid stenosis, central nervous system disorder, cerebrovascular disorder, nervous system disorder, vascular disorder | Active, not recruiting | Not stated | 2026-05-28 | NCT05465122 | |
| Palbociclib and Pembrolizumab in Sarcoma | Neoplasms by Histologic Type, Neoplasms, Connective and Soft Tissue, neoplasm, sarcoma | Recruiting | Phase 1 | 2026-05-22 | NCT06113809 | |
| ONC201 in H3 K27M-mutant Diffuse Glioma Following Radiotherapy (the ACTION Study) | Neoplasms by Histologic Type, Neoplasms, Germ Cell and Embryonal, Neoplasms, Nerve Tissue, epithelial neoplasm, glioma, neoplasm, neuroepithelial neoplasm, primitive neuroectodermal tumor | Recruiting | Phase 3 | 2026-04-16 | NCT05580562 | |
| A Comparison Of Primary TKA Rehabilitation Using A Smart Orthotic Versus Outpatient Physical Therapy | Arthropathy of Knee | Recruiting | Not applicable | 2026-03-25 | NCT04924205 | |
| A Study to Investigate the Safety and Tolerability of Ziftomenib in Combination With Venetoclax/Azacitidine, Venetoclax, 7+3, or 7+3+Quizartinib in Patients With AML | Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, Neoplasms by Site, Neoplasms, Connective and Soft Tissue, acute myeloid leukemia, acute myeloid leukemia with mutated NPM1, hematologic disorder, hematopoietic and lymphoid system neoplasm, leukemia, myeloid leukemia, myeloid sarcoma, neoplasm, sarcoma | Recruiting | Phase 1 | 2026-03-13 | NCT05735184 | |
| Long-Term Follow-up Study | B-cell neoplasm, B-cell non-Hodgkin lymphoma, Blood Protein Disorders, Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, Neoplasms by Site, acute myeloid leukemia, cardiovascular disorder, hematologic disorder, hematopoietic and lymphoid system neoplasm, hemorrhagic disease, immune system disorder, immunoproliferative disorder, leukemia, lymphatic system disorder, lymphoma, lymphoproliferative syndrome, monoclonal gammopathy, myeloid leukemia, neoplasm, non-Hodgkin lymphoma, plasma cell neoplasm, vascular disorder, vascular hemostatic disease | Enrolling by invitation | Not stated | 2026-03-12 | NCT05332054 | |
| Seleno-L Methionine (SLM)-Axitinib-Pembrolizumab | Clear-cell metastatic renal cell carcinoma, Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Male Urogenital Diseases, Neoplasms by Histologic Type, Neoplasms by Site, Urogenital Diseases, Urogenital Neoplasms, adenocarcinoma, benign urinary system neoplasm, carcinoma, clear cell renal carcinoma, epithelial neoplasm, kidney cancer, kidney disorder, neoplasm, renal cell carcinoma, urinary system disorder | Active, not recruiting | Phase 1 / Phase 2 | 2025-12-10 | NCT05363631 |